Bharat Immunolog

How has been the historical performance of the Bharat Immunolog?

Bharat Immunolog has experienced a declining trend in net sales and profitability, with net sales dropping from Rs 124.19 crore in March 2017 to Rs 44.61 crore in March 2023, and losses increasing from Rs 6.75 crore to Rs 17.06 crore in the same period. Despite a positive cash flow from operating activities in March 2023, the overall financial position remains weak.

Answer:<BR>The historical performance of Bharat Immunolog shows a declining trend in net sales and profitability over the years, with significant losses reported in recent periods.<BR><BR>Breakdown:<BR>Bharat Immunolog's net sales have decreased from Rs 124.19 crore in March 2017 to Rs 44.61 crore in March 2023, reflecting a downward trend over the years. The total operating income followed a similar pattern, dropping from Rs 124.19 crore in March 2017 to Rs 44.61 crore in March 2023. The company has faced increasing raw material costs, which peaked at Rs 84.28 crore in March 2019 and fell to Rs 33.04 crore in March 2023. Operating profit margins have deteriorated significantly, with an operating profit margin of -41.38% in March 2023 compared to a positive margin of 9.9% in March 2017. The profit before tax has also worsened, moving from a profit of Rs 9.45 crore in March 2017 to a loss of Rs 22.85 crore in March 2023. Consequently, the profit after tax has shown a similar decline, with losses increasing from Rs 6.75 crore in March 2017 to Rs 17.06 crore in March 2023. The company's total liabilities decreased from Rs 191.70 crore in March 2022 to Rs 158.84 crore in March 2023, while total assets also fell from Rs 191.70 crore to Rs 158.84 crore in the same period. Cash flow from operating activities turned positive in March 2023 at Rs 10.00 crore, contrasting with a negative cash flow of Rs -42.00 crore in March 2022, although the overall cash position remains weak with a closing cash balance of Rs 1.00 crore in March 2023.

When is the next results date for Bharat Immunolog?

No Upcoming Board Meetings

Has Bharat Immunolog declared dividend?

No Dividend History Available

Who are the peers of the Bharat Immunolog?

Bharat Immunolog's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Mercury Labs, Makers Labs, Ind-Swift, and Ajooni Biotech. Bharat Immunolog has below-average management risk and growth, with a 1-year return of -8.98%, higher than Ind-Swift but lower than its other peers.

Peers: The peers of Bharat Immunolog are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Mercury Labs, Makers Labs., Ind-Swift, Ajooni Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Mercury Labs and Onyx Biotec. Below Average management risk is noted for Bharat Immunolog, Makers Labs., and Ajooni Biotech, while Ind-Swift does not qualify. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen in Bharat Immunolog, Divi's Lab., Torrent Pharma, Mercury Labs, Makers Labs., Ajooni Biotech, and the rest. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good is noted for Torrent Pharma, Average for Ajooni Biotech, and Below Average for Bharat Immunolog, Makers Labs., and the rest.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Ind-Swift has the lowest at -19.94%. Bharat Immunolog's 1-year return is -8.98%, which is higher than Ind-Swift but lower than all other peers. Additionally, Mercury Labs, Makers Labs., Ind-Swift, and Ajooni Biotech have negative six-month returns.

Should I buy, sell or hold Bharat Immunolog?

Is Bharat Immunolog overvalued or undervalued?

As of April 5, 2023, Bharat Immunolog is considered overvalued and classified as "risky" due to negative financial metrics, including a PE Ratio of -6.21 and an EV to EBITDA of -10.01, which compare unfavorably to peers like Sun Pharma and Cipla, alongside a 1-year stock return of -8.84% versus the Sensex's 7.62%.

As of 5 April 2023, Bharat Immunolog has moved from a grade of "does not qualify" to "risky." The company is currently overvalued based on its financial metrics. Key ratios include a PE Ratio of -6.21, an EV to EBITDA of -10.01, and a Price to Book Value of 1.43. These figures indicate significant financial distress, particularly highlighted by the negative PE and EV ratios.<BR><BR>In comparison to its peers, Bharat Immunolog's valuation appears unfavorable. For instance, Sun Pharma has a PE Ratio of 35.25, while Cipla stands at 22.99, both indicating a more favorable market perception. The company's recent stock performance has also lagged behind the Sensex, with a 1-year return of -8.84% compared to the Sensex's 7.62%. Overall, the combination of poor financial ratios and unfavorable peer comparisons suggests that Bharat Immunolog is overvalued in the current market environment.

What is the technical trend for Bharat Immunolog?

As of May 13, 2025, Bharat Immunolog's trend is mildly bearish, with mixed signals from MACD, moving averages, and Bollinger Bands across different time frames.

As of 13 May 2025, the technical trend for Bharat Immunolog has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, and the Bollinger Bands show a bullish signal on the weekly chart but mildly bearish on the monthly. The KST is mildly bullish weekly but bearish monthly, and there are no clear trends indicated by Dow Theory on both weekly and monthly time frames. Overall, the current stance is mildly bearish, driven primarily by the mixed signals from moving averages and the monthly MACD.

Who are in the management team of Bharat Immunolog?

As of March 2022, the management team of Bharat Immunolog includes Y K Gupta (Chairman), Sanjay Kumar Mishra (Managing Director), and several independent directors: Alka Sharma, Mohd Aslam, Sudhanshu Vrati, Madhu Dikshit, and Pankaj Kumar, along with Sandip K Lal (Company Secretary).

As of March 2022, the management team of Bharat Immunolog includes the following members:<BR><BR>1. Y K Gupta - Chairman & Independent Director<BR>2. Sandip K Lal - Company Secretary & Compliance Officer<BR>3. Alka Sharma - Independent Director<BR>4. Mohd Aslam - Independent Director<BR>5. Sudhanshu Vrati - Independent Director<BR>6. Madhu Dikshit - Independent Director<BR>7. Sanjay Kumar Mishra - Managing Director<BR>8. Pankaj Kumar - Independent Director<BR><BR>This team comprises a mix of independent directors and key management personnel, each contributing to the governance and operational oversight of the company.

What does Bharat Immunolog do?

Bharat Immunological & Biological Corporation Ltd (BIBCOL) manufactures vaccines and pharmaceutical products and operates as a Central Public Sector Unit. As of September 2023, it reported a net profit of -49 Cr and has a market cap of INR 100 Cr.

Overview: <BR>Bharat Immunological & Biological Corporation Ltd (BIBCOL) is engaged in the manufacture of vaccines and pharmaceutical products within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History: <BR>BIBCOL was incorporated in 1989 and operates as a Central Public Sector Unit under the Department of Biotechnology, Ministry of Science and Technology. The latest quarterly results reported are for September 2023.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: -49 Cr (Quarterly Results - Sep 2023) <BR>Market-cap value: INR 100 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.83 <BR>Return on Equity: -22.96% <BR>Price to Book: 1.27<BR><BR>Contact Details: <BR>Address: BIBCOL OPV Plant Village Chola, Bulandshahr, Uttar Pradesh: 203203 <BR>Tel: 91-5732-238210 <BR>Website: http://www.bibcol.com

Who are the top shareholders of the Bharat Immunolog?

The top shareholders of Bharat Immunolog include the President of India, who holds 59.25% of the shares, while individual investors own 39.47%. There are no mutual funds or foreign institutional investors involved.

The top shareholders of Bharat Immunolog are primarily the promoters, with the President of India holding the largest share at 59.25%. Additionally, individual investors collectively hold 39.47% of the shares. There are currently no mutual funds or foreign institutional investors involved in the company's shareholding.

How big is Bharat Immunolog?

As of 24th July, Bharat Immunological & Biological Corporation Ltd has a market capitalization of 98.00 Cr, with Net Sales of 7.65 Cr and a Net Profit loss of 18.07 Cr over the latest four quarters. Shareholder's Funds are 87.80 Cr, and Total Assets are valued at 158.84 Cr as of March 2023.

As of 24th July, Bharat Immunological & Biological Corporation Ltd has a market capitalization of 98.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Bharat Immunological reported Net Sales of 7.65 Cr. However, the company experienced a loss of 18.07 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2023. Shareholder's Funds stand at 87.80 Cr, while Total Assets are valued at 158.84 Cr.

Which are the latest news on Bharat Immunolog?

Why is Bharat Immunological & Biological Corporation Ltd falling/rising?

As of 17-Mar, Bharat Immunological & Biological Corporation Ltd's stock price is currently at 16.76, reflecting a 2.95% increase today, driven by higher investor participation. However, the stock has underperformed over the past month and year, trading below its moving averages, indicating a longer-term downward trend.

As of 17-Mar, Bharat Immunological & Biological Corporation Ltd's stock price is rising, currently at 16.76, with a change of 0.48 (2.95%) upward. This increase is notable as it has outperformed the sector by 2.67% today. Additionally, there has been a rise in investor participation, with a delivery volume of 14.54 k on 16 March, which is up by 6.23% compared to the 5-day average delivery volume. <BR><BR>However, it is important to note that despite today's positive movement, the stock has been underperforming over longer periods, with declines of 9.55% over the past month and 20.23% over the past year. The stock is also trading below its moving averages across various time frames, indicating a longer-term downward trend. Nonetheless, the current rise in price could be attributed to short-term trading activity and increased investor interest, despite the overall negative performance in the longer term.

Why is Bharat Immunological & Biological Corporation Ltd falling/rising?

As of 18-Mar, Bharat Immunological & Biological Corporation Ltd's stock price is at 16.68, reflecting a decline of 0.48%. The stock has significantly underperformed against the Sensex, with substantial losses over various time frames, indicating a bearish trend.

As of 18-Mar, Bharat Immunological & Biological Corporation Ltd's stock price is falling, currently at 16.68, which reflects a decrease of 0.08 or 0.48%. The stock has underperformed compared to the benchmark Sensex, which has only declined by 0.21% over the same period. Over the past week, the stock has dropped by 1.24%, and its performance over the last month shows a significant decline of 10.85%, compared to an 8.40% drop in the Sensex.<BR><BR>Year-to-date, the stock has fallen by 16.89%, while the Sensex has decreased by only 9.99%. Over the past year, Bharat Immunological has experienced a substantial decline of 20.95%, contrasting sharply with the Sensex's gain of 1.86%. The three-year and five-year performance also indicates a downward trend for the stock, with declines of 28.23% and 67.45%, respectively, while the Sensex has increased by 32.27% and 55.85% in those time frames.<BR><BR>Additionally, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically indicates a bearish trend. Although there has been a slight increase in investor participation, with a 2.01% rise in delivery volume, this has not been sufficient to counteract the overall negative performance. Therefore, the combination of poor relative performance, declining moving averages, and significant losses over multiple periods contributes to the stock's current downward trajectory.

Why is Bharat Immunological & Biological Corporation Ltd falling/rising?

As of 19-Mar, Bharat Immunological & Biological Corporation Ltd's stock price is at 16.65, reflecting a decline of 2.29% and indicating a bearish trend as it trades below all major moving averages. The stock has experienced significant declines over various time frames, including a year-to-date drop of 17.04%, contrasting with the benchmark Sensex's smaller decline.

As of 19-Mar, Bharat Immunological & Biological Corporation Ltd's stock price is falling, currently at 16.65, which reflects a decrease of 0.39 or 2.29%. This decline follows a trend reversal after two consecutive days of gains. The stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. <BR><BR>Additionally, the performance of the stock has been poor over various time frames, with a year-to-date decline of 17.04% compared to a 12.92% drop in the benchmark Sensex. Over the past year, the stock has decreased by 23.87%, while the Sensex has only fallen by 1.65%. The stock's performance over three years shows a significant decline of 28.36%, contrasting sharply with the Sensex's increase of 27.97%. <BR><BR>Investor participation has also decreased, with the delivery volume on March 18 falling by 8.03% against the 5-day average. The overall sector, Pharmaceuticals & Drugs, has seen a decline of 2.13%, which may also be contributing to the downward pressure on Bharat Immunological's stock price.

Why is Bharat Immunological & Biological Corporation Ltd falling/rising?

As of 20-Mar, Bharat Immunological & Biological Corporation Ltd's stock price is at 16.92, showing a short-term increase due to higher investor participation, but it has declined 15.70% year-to-date and 66.33% over the past five years, indicating long-term concerns.

As of 20-Mar, Bharat Immunological & Biological Corporation Ltd's stock price is rising, currently at 16.92, reflecting an increase of 0.27 or 1.62%. This rise can be attributed to a notable increase in investor participation, as evidenced by a delivery volume of 26.3 k on 19 March, which has risen by 74.55% compared to the 5-day average delivery volume. Additionally, the stock's current price is higher than the 5-day moving average, indicating a short-term upward trend. Despite this positive movement, it is important to note that the stock has experienced a decline of 15.70% year-to-date and a significant drop of 66.33% over the past five years, suggesting that while there may be short-term gains, the long-term performance remains concerning.

Why is Bharat Immunological & Biological Corporation Ltd falling/rising?

As of 23-Mar, Bharat Immunological & Biological Corporation Ltd's stock is declining, currently priced at Rs. 16.00, down 4.31%. The stock is underperforming its sector and has weak long-term fundamentals, including a significant drop in net sales and a high debt-equity ratio.

As of 23-Mar, Bharat Immunological & Biological Corporation Ltd's stock price is falling, currently at Rs. 16.00, reflecting a decrease of Rs. 0.72 or 4.31%. This decline is supported by several negative factors highlighted in the recent performance data. The stock has hit a new 52-week low of Rs. 15.66 today and is underperforming its sector by 0.74%. <BR><BR>In terms of moving averages, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, the pharmaceuticals and drugs sector has experienced a decline of 3.62%, which may also contribute to the stock's poor performance.<BR><BR>The company's long-term fundamentals are weak, as it has not declared results in the last six months, and its net sales have decreased significantly by 87.03% over the past nine months. The operating cash flow is reported at the lowest level of INR 0 MM, and the debt-equity ratio is alarmingly high at 83.16%, indicating a low ability to service debt. Over the past five years, the company has seen a negative annual growth rate in net sales of 24.67% and an operating profit decline of 170.32%. <BR><BR>Moreover, the stock has consistently underperformed against the benchmark, generating a return of -26.97% over the last year, while the BSE500 index has only fallen by 5.47% during the same period. This consistent underperformance, coupled with the lack of recent positive financial results, contributes to the stock's current downward trajectory.

Why is Bharat Immunological & Biological Corporation Ltd falling/rising?

As of 24-Mar, Bharat Immunological & Biological Corporation Ltd's stock price has risen slightly to 16.13, but it has experienced significant declines of 19.63% year-to-date and 26.85% over the past year. Despite increased investor participation, the overall trend remains negative, with the stock underperforming compared to the sector and trading close to its 52-week low.

As of 24-Mar, Bharat Immunological & Biological Corporation Ltd's stock price is rising slightly, with a change of 0.12 (0.75%) to a current price of 16.13. However, despite this small increase, the stock has shown a significant decline over various periods. For instance, it has fallen by 3.76% over the past week and 9.48% over the past month. Year-to-date, the stock is down 19.63%, and over the past year, it has decreased by 26.85%. <BR><BR>The stock is currently trading close to its 52-week low, being only 2.91% away from a low of Rs 15.66. Additionally, it is underperforming compared to the sector by 0.37% today and is trading lower than its moving averages across multiple time frames (5-day, 20-day, 50-day, 100-day, and 200-day). <BR><BR>On a more positive note, there has been a notable increase in investor participation, with delivery volume rising by 150.79% against the 5-day average, indicating some interest from investors. Despite this uptick in participation, the overall trend remains negative, with the stock showing substantial declines over longer periods compared to the benchmark Sensex, which has increased by 28.75% over the last three years.

Why is Bharat Immunological & Biological Corporation Ltd falling/rising?

As of 25-Mar, Bharat Immunological & Biological Corporation Ltd's stock price has risen by 1.05% to 16.30, following recent gains and increased investor participation. However, it has underperformed over the past week and year-to-date, trading below all moving averages and nearing its 52-week low.

As of 25-Mar, Bharat Immunological & Biological Corporation Ltd's stock price is currently rising, evidenced by a change of 0.17, or 1.05%, in the current price of 16.30. This increase follows a period of consecutive gains, with the stock having risen 1.81% over the last two days. Additionally, there has been a rise in investor participation, as indicated by a delivery volume of 25.65k on 24 March, which is up by 0.4% compared to the 5-day average delivery volume.<BR><BR>However, it is important to note that despite this recent uptick, the stock has been underperforming in the broader market context. Over the past week, it has declined by 4.34%, and year-to-date, it is down 18.78%, which is significantly worse than the Sensex's decline of 11.67% in the same period. The stock is also trading below all its moving averages, indicating a longer-term downward trend. Furthermore, it is close to its 52-week low, being only 3.93% away from Rs 15.66.<BR><BR>In summary, while there is a short-term rise in the stock price, the overall performance metrics suggest a challenging environment for Bharat Immunological & Biological Corporation Ltd.